These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26294785)

  • 1. Response to Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346.
    Tang A; Rabasa-Lhoret R; Castel H; Wartelle-Bladou C; Gilbert G; Massicotte-Tisluck K; Chartrand G; Olivié D; Julien AS; de Guise J; Soulez G; Chiasson JL
    Diabetes Care; 2015 Sep; 38(9):e150-1. PubMed ID: 26294785
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346.
    Shan PF; Ji XL; Wang L; Li P; Ren YZ
    Diabetes Care; 2015 Sep; 38(9):e148-9. PubMed ID: 26294784
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.
    Tang A; Rabasa-Lhoret R; Castel H; Wartelle-Bladou C; Gilbert G; Massicotte-Tisluck K; Chartrand G; Olivié D; Julien AS; de Guise J; Soulez G; Chiasson JL
    Diabetes Care; 2015 Jul; 38(7):1339-46. PubMed ID: 25813773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
    Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
    J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).
    Nomoto H; Miyoshi H; Furumoto T; Oba K; Tsutsui H; Miyoshi A; Kondo T; Tsuchida K; Atsumi T; Manda N; Kurihara Y; Aoki S;
    PLoS One; 2015; 10(8):e0135854. PubMed ID: 26284918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.
    Ten Kulve JS; Veltman DJ; van Bloemendaal L; Barkhof F; Drent ML; Diamant M; IJzerman RG
    Diabetes Care; 2016 Feb; 39(2):214-21. PubMed ID: 26283736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice.
    Li Y; Zheng J; Shen Y; Li W; Liu M; Wang J; Zhu S; Wu M
    Med Sci Monit; 2018 May; 24():3293-3300. PubMed ID: 29777582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.
    Orchard TJ; Cariou B; Connelly MA; Otvos JD; Zhang S; Antalis CJ; Ivanyi T; Hoogwerf BJ
    Cardiovasc Diabetol; 2017 Jun; 16(1):73. PubMed ID: 28587667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of liraglutide in mice with diet-induced obesity studied by metabolomics.
    Bugáňová M; Pelantová H; Holubová M; Šedivá B; Maletínská L; Železná B; Kuneš J; Kačer P; Kuzma M; Haluzík M
    J Endocrinol; 2017 Apr; 233(1):93-104. PubMed ID: 28138003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
    Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
    Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes.
    Davenport C; Mahmood WA; Forde H; Ashley DT; Agha A; McDermott J; Sreenan S; Thompson CJ; McGrath F; McAdam B; Cummins PM; Smith D
    Eur J Endocrinol; 2015 Jul; 173(1):53-61. PubMed ID: 26036811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
    Arturi F; Succurro E; Miceli S; Cloro C; Ruffo M; Maio R; Perticone M; Sesti G; Perticone F
    Endocrine; 2017 Sep; 57(3):464-473. PubMed ID: 27830456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Upala S
    Hepatology; 2019 May; 69(5):2303-2304. PubMed ID: 30734333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic adenylate cyclase 3 is upregulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity.
    Liang Y; Li Z; Liang S; Li Y; Yang L; Lu M; Gu HF; Xia N
    Nutr Diabetes; 2016 Jan; 6(1):e191. PubMed ID: 26807509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting Insulin Analogs Effect on gh/igf Axis of Children with Type 1 Diabetes: a Randomized, Open-label, Two-period, Cross-over Trial.
    Cherubini V; Pintaudi B; Iannilli A; Pambianchi M; Ferrito L; Nicolucci A
    Exp Clin Endocrinol Diabetes; 2016 May; 124(5):276-82. PubMed ID: 27023008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M
    J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes.
    Xu P; Ye X; Zhang Y; Yuan Q; Liu M; Wu Q; Ren G; Li D
    J Diabetes Complications; 2015; 29(1):5-12. PubMed ID: 25456819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
    Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study.
    Yamamoto S; Hayashi T; Ohara M; Goto S; Sato J; Nagaike H; Fukase A; Sato N; Hiromura M; Tomoyasu M; Nakanishi N; Lee S; Osamura A; Yamamoto T; Fukui T; Hirano T
    Diabetes Res Clin Pract; 2018 Jun; 140():339-346. PubMed ID: 29588170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoglycemia affects the changes in endothelial progenitor cell levels during insulin therapy in type 2 diabetic patients.
    Fadini GP; Albiero M; Vigili de Kreutzenberg S; Avogaro A
    J Endocrinol Invest; 2015 Jul; 38(7):733-8. PubMed ID: 25722222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.